Not many medical researchers have more incentive than Dr Graham Kelly.

While working to develop drugs that make cancer treatments work better, the 71-year-old developed prostate cancer himself.

After exhausting all treatment options, Dr Kelly decided to take a chance on his own experimental drug – which had only ever worked in the laboratory.

“I was facing death — there’s no other way of putting it,’’ he later told Tim Boreham in The Australian.

The cancer-surviving doc was then the CEO of Novogen (ASX:NRT), a biotech group once worth $800 million.

These days Novogen is worth around $20 million and Dr Kelly continues his research with new drug developer, Noxopharm (ASX:NOX), which listed last year in a $6 million Initial Public Offering.

The drug, known these days as NOX66, works in conjunction with current chemotherapy drugs and radiation therapy which targets the source of a cancer.

Noxopharm, currently promoting NOX66 on a roadshow through Singapore and Hong Kong, plans to report on initial trial results before Christmas – and have a drug on the market within five years.

Read more at Stockhead